Drugs / OPC-415
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04649073 | Feb 2021 → Apr 2025 overdue | plasma cell myeloma | Otsuka Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC-415 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04649073 ↗ |